Patterns and safety of glucocorticosteroid use following CD19 CAR‐T therapy for large B‐cell lymphoma

Abstract Corticosteroids are commonly used to manage cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) following chimeric antigen receptor (CAR) T‐cell therapy, and yet, their dose‐specific impact on outcomes remains uncertain. We retrospectively eval...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Efrat Luttwak, David Nemirovsky, Sean M. Devlin, Alexander P. Boardman, Giulio Cassanello, Magdalena Corona, Danny Luan, Parastoo B. Dahi, Alejandro Luna De Abia, Lorenzo Falchi, Ivan Landego, Richard J. Lin, Jeniffer K. Lue, Lia M. Palomba, Jae H. Park, Sandeep S. Raj, Kai Rejeski, Alfredo Rivas Delgado, Michael Scordo, Ana Alarcon Tomas, Gunjan L. Shah, Miguel‐Angel Perales, Gilles Salles, Roni Shouval
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2025-11-01
Serija:	HemaSphere
Online dostop:	https://doi.org/10.1002/hem3.70248
Oznake:	Označite Brez oznak, prvi označite!